Govt moves to make three key cancer drugs cheaper
- Cauvery row: Can't release water till December, Karnataka tells SC
- India beat New Zealand by 197 runs in Kanpur Test, take 1-0 series lead
- ISRO successfully places SCATSAT-1, seven other satellites in orbit
- Shahabuddin bail case: Supreme Court adjourns hearing for Wednesday
- SC refuses urgent hearing on PIL seeking to declare Indus Waters Treaty unconstitutional
In a move that will benefit thousands of cancer patients but is likely to upset pharma MNCs, the Department of Pharmaceuticals has started the process of issuing compulsory licences for three commonly used anti-cancer drugs, Trastuzumab (or Herceptin, used for breast cancer), Ixabepilone (used for chemotherapy) and Dasatinib (used to treat leukaemia).
Compulsory licensing (CL) by the government allows a domestic company to manufacture and sell a generic version of a patented drug with or without the consent of the patent-holder. Sections 84 and 92 of the Indian Patents Act, 1970, provide for CL in cases where the patented drug is unavailable, unaffordable, or if there are problems with its supply in India. CL reduces the price of a drug manifold, and is a practice in many developing countries.
The first drug to be issued a compulsory licence in India was Bayer's Nexavar (sorafenib tosylate), a drug for liver cancer, last August. After the CL, Nexavar is available for Rs 8,880 per pack of 120 tablets (a month's dose), over 95% cheaper than its pre-CL price.
Trastuzumab, Ixabepilone and Dasatinib are all more expensive that Nexavar, costing Rs 50,000, Rs 70,000-80,000 and Rs 15,000 respectively for a month's dose.
- Any response to Uri must factor in Pakistani state’s relationship with non-state actors
- It is assumed that Blacks will vote 93 per cent for Clinton, seven per cent for Trump
- As Russia draws closer to Pakistan and China, India must stop taking it for granted
- A year after, the new constitution is owned only by the political elite
- India urgently wants sporting greatness — but its desire is fraught with dangers
- Loud jingoism and war talk erode India’s credibility